TD Asset Management
ATRA icon

TD Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

TD Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,472
Closed -$303K – 1368
2024
Q1 		$303K Buy
+17,472
New +$310K ﹤0.01% 1338
2019
Q3 		– Sell
-541
Closed -$272K – 1336
2019
Q2 		$272K Sell
541
-1,479
-73% -$1.04M ﹤0.01% 1261
2019
Q1 		$2.01M Buy
2,020
+148
+8% +$138K ﹤0.01% 907
2018
Q4 		$1.63M Buy
1,872
+52
+3% +$48.3K ﹤0.01% 961
2018
Q3 		$1.88M Buy
1,820
+96
+6% +$93.9K ﹤0.01% 1009
2018
Q2 		$1.58M Buy
1,724
+80
+5% +$85.9K ﹤0.01% 1014
2018
Q1 		$1.6M Buy
+1,644
New +$1.5M ﹤0.01% 940

Other funds holding ATRA

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

TD Asset Management's ATRA Position: Q2 2024 in Review

TD Asset Management sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 17,472 shares — an estimated $303K sold.

TD Asset Management first reported a position in ATRA in Q1 2018 and held it in 7 quarters. The position peaked at $2.01M in Q1 2019. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • TD Asset Management reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • TD Asset Management sold 17,472 Atara Biotherapeutics shares in Q2 2024, an estimated $303K.
  • TD Asset Management first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 7 quarters.
  • TD Asset Management's Atara Biotherapeutics position peaked at $2.01M in Q1 2019.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on TD Asset Management's 13F filing for Q2 2024, filed 2 Aug 2024.